Indications & formulation #
Major depressive disorder in adults. This reference covers the selected formulation; other indications and products need their own evidence.
Dose reference #
Adult educational reference · Oral tablet · United States. The clinician selects treatment after assessment; this page does not calculate or change a prescription.
Start 15 mg at night; reassess at intervals of at least 1–2 weeks before changing dose. Maximum 45 mg/day.
Contraindications & important cautions #
Avoid MAOIs. Review sedation, weight gain, serious skin reactions and symptoms suggesting neutropenia.
Selected important cautions; consult the full product information for all contraindications and warnings.
Adverse effects #
Sedation, appetite and weight changes can be clinically important.
Interactions #
Review additive sedation, alcohol and other relevant centrally acting or serotonergic medicines.
Monitoring #
Track weight/appetite, daytime function, mood and tolerability; assess organ function and symptoms suggesting rare serious adverse effects.
Special populations #
Reduced clearance in moderate/severe renal or hepatic impairment may require lower doses. Older adults have greater sedation/falls vulnerability.
Adult scope. Pregnancy, breastfeeding and pediatric use require the exact product’s population-specific guidance and individual assessment.
Discontinuation, restarting & counseling #
Taper gradually; assess sleep, appetite and withdrawal symptoms.
Condition-specific prescribing #
Additional indication-specific records retain their own formulation and source context.
Mirtazapine
Major depressive disorder
Adults · Immediate-release tablets · Oral · United States product labeling
- Starting dose
- 15 mg once daily, usually at bedtime.
- Titration
- Allow at least 1–2 weeks between dose changes.
- Treatment range / target
- 15–45 mg/day.
- Maximum / limits
- 45 mg/day.
- Trial & duration
- Continue according to response, remission and recurrence history; taper rather than abruptly stop.
- Monitoring
- Sedation, appetite, weight, metabolic effects and activation; fever/sore throat warrants assessment for blood dyscrasia.
- Population & organ-function adjustments
- Clearance is reduced in renal/hepatic impairment and older adults; dosage reduction may be necessary.
- Important cautions
- Avoid MAOIs; consider additive sedation, hyponatraemia, QT vulnerability and rare severe skin reactions.
Brands & products #
Historical catalogue observations. Prices and catalogue presence do not establish current availability or Indian approval.
Reference coverage #
Structured summary of selected adult uses, not an exhaustive monograph. Indian product authorization and local prescribing requirements have not been reconciled.
References · 2
- Mirtazapine — Oral tablet — selected prescribing information · United States · Checked 2026-10-27 · Selected formulation: Oral tablet · Supports indications, dose, cautions, adverse effects, interactions, monitoring, special populations and stopping. Source sections: Indications and usage; Dosage and administration; Contraindications; warnings and precautions; Use in specific populations; patient counseling
- Mirtazapine tablets — product label, sections 2, 5 and 8 · United States · Checked 2026-10-26 · Supports: Mirtazapine — Major depressive disorder (Immediate-release tablets)